Advanced search
Publication Cover
OncoImmunology Volume 10, 2021 - Issue 1
Submit an article Journal homepage
3,113
Views
11
CrossRef citations to date
0
Altmetric
Original Research

Association of PIK3CA mutation and PTEN loss with expression of CD274 (PD-L1) in colorectal carcinoma

Tomotaka Ugaia Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA;b Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USAView further author information
,
Melissa Zhaoa Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USAView further author information
,
Takashi Shimizuc Department of Cardiovascular Medicine, Graduate School of Medicine, the University of Tokyo, Tokyo, JapanView further author information
,
Naohiko Akimotoa Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USAView further author information
,
Shanshan Shia Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USAView further author information
,
Yasutoshi Takashimaa Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USAView further author information
,
Rong Zhonga Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USAView further author information
,
Mai Chan Laua Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USAView further author information
,
Koichiro Harukia Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USAView further author information
,
Kota Arimaa Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USAView further author information
,
Kenji Fujiyoshia Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USAView further author information
,
Benjamin Langworthyb Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USAView further author information
,
Yohei Masugia Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USAView further author information
,
Annacarolina da Silvaa Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USAView further author information
,
Katsuhiko Noshoa Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USAView further author information
,
Yoshifumi Babaa Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USAView further author information
,
Mingyang Songd Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA;e Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA;f Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USAView further author information
,
Andrew T. Chane Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA;f Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA;g Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA;h Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USAView further author information
,
Molin Wangb Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA;g Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA;i Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USAView further author information
,
Jeffrey A. Meyerhardtj Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USAView further author information
,
Marios Giannakisj Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA;k Broad Institute of MIT and Harvard, Cambridge, MA, USA;l Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USAView further author information
,
Juha P. Väyrynena Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA;j Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA;m Cancer and Translational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital, and University of Oulu, Oulu, FinlandORCID Iconhttps://orcid.org/0000-0002-8683-2996View further author information
ORCID Icon,
Jonathan A. Nowaka Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USAView further author information
&
Shuji Oginoa Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA;b Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA;k Broad Institute of MIT and Harvard, Cambridge, MA, USA;n Cancer Immunology and Cancer Epidemiology Programs, Dana-Farber Harvard Cancer Center, Boston, MA, USACorrespondence[email protected]
View further author information
 show all
Article: 1956173 | Received 06 May 2021, Accepted 12 Jul 2021, Published online: 02 Aug 2021

Figures & data

Figure 1. Flow diagram of study population in the nurses’ health study and the health professionals follow-up study

Figure 1. Flow diagram of study population in the nurses’ health study and the health professionals follow-up study

Figure 2. Tumor CD274 and PTEN expression in colorectal cancer. Tumor CD274 expression was evaluated based on immunostaining in the cytoplasm and membrane of tumor cells. Tumor CD274 expression was interpreted as negative (a), low (b), or high (c) according to membranous and cytoplasmic intensity. Tumor PTEN expression was evaluated based on immunostaining in the cytoplasm and nuclear of tumor cells. Cytoplasmic and nuclear PTEN expression level was classified as lost (d) or intact (e) according to cytoplasmic and nuclear intensity. Scale bars represent 50 μm

Figure 2. Tumor CD274 and PTEN expression in colorectal cancer. Tumor CD274 expression was evaluated based on immunostaining in the cytoplasm and membrane of tumor cells. Tumor CD274 expression was interpreted as negative (a), low (b), or high (c) according to membranous and cytoplasmic intensity. Tumor PTEN expression was evaluated based on immunostaining in the cytoplasm and nuclear of tumor cells. Cytoplasmic and nuclear PTEN expression level was classified as lost (d) or intact (e) according to cytoplasmic and nuclear intensity. Scale bars represent 50 μm

Table 1. Clinical, pathological, and molecular characteristics of colorectal cancer cases according to PIK3CA mutation and PTEN expression in tumor tissue

Table 2. Inverse probability weighting-adjusted ordinal logistic regression analysis to assess the association of tumor PIK3CA mutation or PTEN expression (predictor) with CD274 (PD-L1) expression (outcome)

Table 3. CD274 (PD-L1) expression score according to PIK3CA mutation and PTEN expression in tumor tissue

Table 4. Inverse probability weighting-adjusted ordinal logistic regression analysis to assess the association of the combination of PIK3CA mutation and PTEN expression (predictor) with CD274 (PD-L1) expression (outcome)

Supplemental material

Supplemental Material

Download ()

Availability of data and materials

The datasets generated and/or analyzed in this study are not publicly available. Further information including the procedures to obtain and access data from the Nurses’ Health Studies and the Health Professionals

Follow-up Study are described at https://www.nurseshealthstudy.org/researchers/ and

https://sites.sph.harvard.edu/hpfs/for-collaborators/.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.